NCT00463073已完成2 期
A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 6
研究概览
简要总结
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 % of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor prognosis, so innovative therapies are needed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Histological verification of primary GBM
- •Recurrence or progression after standard treatment (debulking surgery of possible, radiotherapy and temozolamide within last six months)
- •Evidence of measurable recurrent progressive primary GBM (CT/MRI scan)
- •PS 0-2 (ECOG scale)
- •Age > 18
- •Life expectancy > 3 month
- •Normal organ function:
- •Platelets > 125 x 109/l
- •Hemoglobin >6,2 mmol/l
- •Leukocytes > 3 x 109/l
- •ACN> 1,5 x 109/l
- •ASAT and/or ALAT < 3 x upper normal limit
- •Bilirubin < 1,5 x upper normal limit
- •Creatinine clearance > 45 ml/min
- •Creatinine < 1,5 x upper normal limit
- •APTT < normal limit
- •INR < normal limit
- •Cholesterol < 7 mmol/l
- •Fertile females must use oral contraceptive, IUD (intrauterine device) or preservatives. Fertile males must use preservatives.
- •Exclusion criteria:
- •Radiotherapy or chemotherapy within the last 4 weeks.
- •Co-medication that may interfere with study results; e.g. immunosuppressive agents other than corticosteroids
- •Prior EGFR- or VEGFR- based therapy.
- •Any condition (medical, social, psychological), which would prevent adequate information and follow-up
- •Any other active malignancy or previous malignancies within the last 5 years, except, adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ.
- •No hypercholesterolemia or hypertriglyceridemia (despite lipid-lowering therapy).
- •Any significant cardiac disease (New York Heart Association Class II or greater), arrhythmia, congestive heart failure, acute myocardial infarction within 6 months or unstable angina pectoris.
- •Clinically significant peripheral vascular disease
- •Evidence of bleeding diathesis, coagulapathy or taking ASA, NSAIDs or clopidogrel
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the curse of the study
- •Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0
- •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 month prior to day 0
- •History of known HIV, Hepatitis B and Hepatitis C negative
- •Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound, ulcer or bone fracture
- •Pregnancy or breast feeding
- •Requires therapeutic anti-coagulation
- •Blood pressure > 150/100 mmHG
- •Grade 2 or greater proteinuria
排除标准
- 未提供
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard TherapyBrain NeoplasmsGliomaNCT00463203Rigshospitalet, Denmark54
终止
2 期
Panitumumab and Irinotecan for Malignant GliomasMalignant Glioma of BrainNCT01017653Annick Desjardins16
已完成
2 期
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal CancerColorectal CancerNCT00483834University Health Network, Toronto50
已完成
2 期
Bevacizumab Beyond Progression (BBP)Malignant GliomaGrade 4 Malignant GliomaGliosarcomaGlioblastomaNCT01740258Duke University68
已完成
2 期
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyAdvanced Colorectal CarcinomaMetastatic Colon AdenocarcinomaMetastatic Rectal AdenocarcinomaRecurrent Colon AdenocarcinomaRecurrent Colorectal AdenocarcinomaRecurrent Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Colorectal CarcinomaUnresectable Rectal AdenocarcinomaNCT04109924Roswell Park Cancer Institute42